Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

March 4, 2008 | Corporate News | English

Invitrogen Corporation Announces Strategic Collaboration with Tecan

Partnership provides integrated instrumentation and reagent solutions

Carlsbad, Calif., March 04, 2008 - Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and Tecan, a global leader in laboratory automation and detection, are entering into a collaboration agreement to validate the compatibility of Invitrogen’s reagents with Tecan’s microplate detection instruments.

Invitrogen’s drug discovery products will be validated on selected Tecan microplate readers and instruments, starting with the Infinite® series readers. Initial certifications will focus on Invitrogen’s assay systems for key target classes, such as LanthaScreen™ TR-FRET for protein kinases, GeneBLAzer® reporter-gene technology for G protein-coupled receptors and Adapta™, a new TR-FRET assay system for lipid kinases. This collaboration will allow Tecan and Invitrogen to develop and promote joint applications for the drug discovery market.

“Through this partnership with Tecan, we will be able to provide integrated instrumentation and reagent solutions to the research community. Previously, this has been a major source of frustration when researchers find that selected technologies are not compatible with the instrument and visa versa,” said John Printen, Invitrogen director of cell signaling. “Our goal is to enable researchers to easily select the right Invitrogen assay system for optimum performance on Tecan instruments.”

“This program will significantly help researchers in drug discovery and the life sciences to speed up assay development and screening programs. Integrated instrumentation and reagent solutions will make it much easier to rapidly optimize for individual assay conditions, thereby increasing the efficiency of the drug discovery process,” said Siegfried Sasshofer, head of sales and marketing for Tecan’s detection business.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.

About Tecan

Tecan (www.tecan.com) is a leading global supplier of solutions for the biopharma, forensic and diagnostic industries. The company is a leader in the development, production and distribution of advanced automation and detection solutions for the world’s leading life science laboratories. Through its REMP subsidiary (www.remp.com), Tecan is the premier supplier of large-scale automated laboratory storage and logistics systems. Its customers include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has over 1100 employees, owns production, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2006, Tecan achieved sales of CHF 405.9 million (USD 324.7 million; EUR 258.6 million). Shares of the Tecan Group are traded on the SWX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Sec. no.: 1210019).

For further information please contact:

Tecan Group Ltd.
Karin Schneider
Seestrasse 103
CH-8708 Männedorf

T +41 44 922 81 11
F +41 44 922 81 12